In response to multiple forms of cellular stress, levels of the O-GlcNAc protein modification are elevated rapidly and dynamically on myriad nucleocytoplasmic proteins (19) . Several studies demonstrate that elevation of O-GlcNAc preceding heat stress (6, 16, 19) , trauma hemorrhage (11, 17, 20) , and ischemia-reperfusion injury (1, 3, (7) (8) (9) (10) (13) (14) (15) is protective, suggesting that increased O-GlcNAc in response to stress is a survival response of cells. The exact molecular mechanism(s) by which O-GlcNAc regulates protein function leading to cellular protection have not been identified. However, OGlcNAc has been shown to regulate the following pathways in a manner consistent with stress tolerance: 1) heat shock protein levels (19) , 2) protein solubility (6, 16) (20) . Thus there is growing evidence to suggest that O-GlcNAc is a novel endogenously recruitable protective agent that modulates numerous proteins and cellular pathways to affect cellular survival and that O-GlcNAc-modulated cellular protection is relevant to diverse models of cellular injury.
In the studies discussed above, O-GlcNAc protein modification levels were raised before cellular injury was initiated. Although it would be possible to treat high-risk patients with prophylactic glucosamine, analogous to aspirin treatment, it would be ideal if O-GlcNAc levels could be raised postinjury and still result in cellular protection. In their report, Liu et al. (8) tested this scenario by raising O-GlcNAc levels postischemia in hearts during reperfusion with either glucosamine or PUGNAc (an inhibitor of O-GlcNAc removal; Fig. 1, bottom) . With the use of a hanging heart model, both glucosamine and PUGNAc treatments increased O-GlcNAc levels during reperfusion and increased cellular ATP levels. Moreover, increased O-GlcNAc during reperfusion was associated with reduced cardiac troponin I release, suggesting improved cardiac recovery. Previously, these authors demonstrated that O-GlcNAc attenuated Ca 2ϩ influx into cells during reperfusion, and consistent with these observations, both glucosamine and PUGNAc were shown to attenuate ␣-fodorin proteolysis, which is presumably mediated by calpain. Moreover, increased glycosylation levels were associated with lower end-diastolic pressure (EDP), which is consistent with decreased Ca 2ϩ upon reperfusion. Interestingly, PUGNAc was shown to increase the total levels of Ca 2ϩ /calmodulin-dependent protein kinase II (CaMKII), resulting in an altered ratio of unphosphorylated to phosphorylated CaMKII. Together, these data suggest that raising O-GlcNAc levels postinjury will result in increased survival of heart tissue and decreased mortality rates (8) . However, this concept is yet to be fully tested in whole animal models of ischemia-reperfusion injury. The next step is to understand how O-GlcNAc is regulating proteins in the heart, resulting in cellular survival. Presumably, this will require a comprehensive proteomic analysis of O-GlcNAc-modified cardiac proteins, with a focus on identifying and studying those proteins that display altered O-GlcNAc protein modification levels during cardiac injury or disease.
In contrast to the data discussed above, O-GlcNAc has been shown to negatively affect cardiac function in diabetic models (Fig. 2, right) . Hyperglycemia, or overexpression of OGT, is associated with prolonged Ca 2ϩ transients and reduced protein and mRNA expression of the sarcoplasmic reticulum Ca 2ϩ -ATPase 2A (SERCA2A) protein. In myocytes or perfused hearts isolated from streptozotocin-induced diabetic mice, overexpression of O-GlcNAcase restored SERCA2A protein levels and calcium handling (2, 5) . Currently, our understanding of the mechanisms dictating whether O-GlcNAc is protective or sensitizes cells to injury is in its infancy. Only further research identifying the molecular mechanisms by which OGlcNAc alters cellular response to injury, the pathways that regulate O-GlcNAc biosynthesis in response to injury, and how these proteins/pathways are differentially regulated in the diabetic heart will reconcile the apparent paradox that exists between the role of O-GlcNAc in regulating protein function in nondiabetic and diabetic hearts.
